KNApSAcK Metabolite C00023362
Metabolite
KNApSAcK Entry
| id | C00023362 |
|---|---|
| Name | Andrographolide |
| CAS RN | 5508-58-7 |
| Standard InChI | InChI=1S/C20H30O5/c1-12-4-7-16-19(2,9-8-17(23)20(16,3)11-21)14(12)6-5-13-15(22)10-25-18(13)24/h5,14-17,21-23H,1,4,6-11H2,2-3H3/b13-5+/t14-,15-,16+,17-,19+,20+/m1/s1 |
| Standard InChI (Main Layer) | InChI=1S/C20H30O5/c1-12-4-7-16-19(2,9-8-17(23)20(16,3)11-21)14(12)6-5-13-15(22)10-25-18(13)24/h5,14-17,21-23H,1,4,6-11H2,2-3H3 |
Cluster
| Phytochemical cluster | No. 46 |
|---|---|
| KCF-S cluster | No. 660 |
Link
ChEMBL
| By standard InChI | CHEMBL186141 |
|---|---|
| By standard InChI Main Layer | CHEMBL186141 CHEMBL191892 CHEMBL364257 CHEMBL479285 CHEMBL466345 CHEMBL1317036 CHEMBL1317931 CHEMBL1599649 CHEMBL1705045 CHEMBL1951638 |
KEGG
| By LinkDB | C20214 |
|---|
CTD
| By CAS RN | C030419 |
|---|
Species
Summary
Plant class
| class name | count |
|---|---|
| asterids | 1 |
Family
| family name | count |
|---|---|
| Acanthaceae | 1 |
List (1)
* NCBI
| KNApSAcK organism | *ID | *family | *plant class | *kingdom |
|---|---|---|---|---|
| Andrographis paniculata | 175694 | Acanthaceae | asterids | Viridiplantae |
Human Protein / Gene in interaction
21 ChEMBL Protein in interactions
| accession | description | class description | compound | assay ID (# of activities) |
# of diseases
(OMIM / KEGG) |
|---|---|---|---|---|---|
| P04637 | Cellular tumor antigen p53 | Transcription Factor | CHEMBL1317036 CHEMBL1599649 |
CHEMBL1613992
(2)
CHEMBL1613995
(2)
|
7 / 44 |
| Q99700 | Ataxin-2 | Unclassified protein | CHEMBL1317931 CHEMBL1705045 |
CHEMBL2114784
(2)
|
1 / 1 |
| Q9H227 | Cytosolic beta-glucosidase | Enzyme | CHEMBL186141 |
CHEMBL865095
(1)
|
0 / 0 |
| Q13526 | Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Enzyme | CHEMBL1705045 |
CHEMBL1794585
(1)
|
0 / 0 |
| P02545 | Prelamin-A/C | Unclassified protein | CHEMBL1599649 |
CHEMBL1614544
(1)
|
11 / 10 |
| P04278 | Sex hormone-binding globulin | Secreted protein | CHEMBL191892 CHEMBL364257 |
CHEMBL831260
(2)
|
0 / 0 |
| Q92830 | Histone acetyltransferase KAT2A | Enzyme | CHEMBL1599649 |
CHEMBL1738606
(1)
|
0 / 0 |
| P84022 | Mothers against decapentaplegic homolog 3 | Unclassified protein | CHEMBL1705045 |
CHEMBL1794584
(1)
|
2 / 0 |
| O75496 | Geminin | Unclassified protein | CHEMBL1317931 CHEMBL1599649 CHEMBL1705045 |
CHEMBL2114843
(3)
CHEMBL2114780
(3)
|
0 / 0 |
| Q04206 | Transcription factor p65 | Transcription Factor | CHEMBL186141 |
CHEMBL2167618
(1)
|
0 / 0 |
| P83916 | Chromobox protein homolog 1 | Unclassified protein | CHEMBL1317931 |
CHEMBL1794401
(1)
|
0 / 0 |
| Q9HC16 | DNA dC->dU-editing enzyme APOBEC-3G | Enzyme | CHEMBL1705045 |
CHEMBL1963863
(1)
|
0 / 0 |
| Q96QE3 | ATPase family AAA domain-containing protein 5 | Unclassified protein | CHEMBL1317931 |
CHEMBL1738588
(1)
CHEMBL1738317
(1)
|
0 / 0 |
| P31749 | RAC-alpha serine/threonine-protein kinase | Akt | CHEMBL186141 |
CHEMBL2167408
(1)
CHEMBL2167409
(1)
CHEMBL2167410 (1) CHEMBL2167411 (1) CHEMBL2167424 (1) CHEMBL2167425 (1) |
4 / 1 |
| P08684 | Cytochrome P450 3A4 | Cytochrome P450 3A4 | CHEMBL1317036 CHEMBL1599649 |
CHEMBL1614108
(2)
CHEMBL1613886
(2)
|
0 / 1 |
| Q16236 | Nuclear factor erythroid 2-related factor 2 | Unclassified protein | CHEMBL1317931 CHEMBL1705045 |
CHEMBL1738184
(1)
CHEMBL2114908
(2)
|
0 / 0 |
| O43451 | Maltase-glucoamylase, intestinal | Hydrolase | CHEMBL186141 |
CHEMBL865093
(1)
CHEMBL886165
(1)
|
0 / 0 |
| O75874 | Isocitrate dehydrogenase [NADP] cytoplasmic | Enzyme | CHEMBL1705045 |
CHEMBL2354311
(1)
|
1 / 0 |
| O00255 | Menin | Unclassified protein | CHEMBL1317036 |
CHEMBL1614531
(1)
|
2 / 5 |
| Q03164 | Histone-lysine N-methyltransferase 2A | Enzyme | CHEMBL1317036 |
CHEMBL1614531
(1)
|
1 / 3 |
| P01215 | Glycoprotein hormones alpha chain | Unclassified protein | CHEMBL1317931 |
CHEMBL2114913
(1)
|
0 / 3 |
CTD interaction (52)
| compound | gene | gene name | gene description | interaction | interaction type | form |
reference
pmid |
|---|---|---|---|---|---|---|---|
| C030419 | 581 |
BAX
BCL2L4 |
BCL2-associated X protein | andrographolide affects the folding of BAX protein |
affects folding
|
protein |
19097688
|
| C030419 | 581 |
BAX
BCL2L4 |
BCL2-associated X protein | Fluorouracil promotes the reaction [andrographolide affects the folding of BAX protein] |
affects folding
/ increases reaction |
protein |
19097688
|
| C030419 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | andrographolide results in increased activity of CASP3 protein |
increases activity
|
protein |
19097688
|
| C030419 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | CASP8 affects the reaction [Fluorouracil promotes the reaction [andrographolide results in increased activity of CASP3 protein]] |
affects reaction
/ increases activity / increases reaction |
protein |
19097688
|
| C030419 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | Fluorouracil promotes the reaction [andrographolide results in increased activity of CASP3 protein] |
increases activity
/ increases reaction |
protein |
19097688
|
| C030419 | 841 |
CASP8
ALPS2B CAP4 Casp-8 FLICE MACH MCH5 |
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) | andrographolide results in increased activity of CASP8 protein |
increases activity
|
protein |
19097688
|
| C030419 | 841 |
CASP8
ALPS2B CAP4 Casp-8 FLICE MACH MCH5 |
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) | CASP8 affects the reaction [Fluorouracil promotes the reaction [andrographolide results in increased activity of CASP3 protein]] |
affects reaction
/ increases activity / increases reaction |
19097688
|
|
| C030419 | 841 |
CASP8
ALPS2B CAP4 Casp-8 FLICE MACH MCH5 |
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) | CASP8 affects the reaction [Fluorouracil promotes the reaction [andrographolide results in increased activity of CASP9 protein]] |
affects reaction
/ increases activity / increases reaction |
19097688
|
|
| C030419 | 841 |
CASP8
ALPS2B CAP4 Casp-8 FLICE MACH MCH5 |
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) | CASP8 results in increased susceptibility to [andrographolide co-treated with Fluorouracil] |
affects cotreatment
/ increases response to substance |
19097688
|
|
| C030419 | 841 |
CASP8
ALPS2B CAP4 Casp-8 FLICE MACH MCH5 |
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) | Fluorouracil promotes the reaction [andrographolide results in increased activity of CASP8 protein] |
increases activity
/ increases reaction |
protein |
19097688
|
| C030419 | 842 |
CASP9
APAF-3 APAF3 ICE-LAP6 MCH6 PPP1R56 |
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) | andrographolide results in increased activity of CASP9 protein |
increases activity
|
protein |
19097688
|
| C030419 | 842 |
CASP9
APAF-3 APAF3 ICE-LAP6 MCH6 PPP1R56 |
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) | CASP8 affects the reaction [Fluorouracil promotes the reaction [andrographolide results in increased activity of CASP9 protein]] |
affects reaction
/ increases activity / increases reaction |
protein |
19097688
|
| C030419 | 842 |
CASP9
APAF-3 APAF3 ICE-LAP6 MCH6 PPP1R56 |
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) | Fluorouracil promotes the reaction [andrographolide results in increased activity of CASP9 protein] |
increases activity
/ increases reaction |
protein |
19097688
|
| C030419 | 890 |
CCNA2
CCN1 CCNA |
cyclin A2 | andrographolide inhibits the reaction [CCNA2 protein binds to CDK2 protein] |
affects binding
/ decreases reaction |
protein |
18619950
|
| C030419 | 890 |
CCNA2
CCN1 CCNA |
cyclin A2 | andrographolide results in decreased expression of CCNA2 protein |
decreases expression
|
protein |
18619950
|
| C030419 | 595 |
CCND1
BCL1 D11S287E PRAD1 U21B31 |
cyclin D1 | andrographolide inhibits the reaction [CCND1 protein binds to CDK4 protein] |
affects binding
/ decreases reaction |
protein |
18619950
|
| C030419 | 595 |
CCND1
BCL1 D11S287E PRAD1 U21B31 |
cyclin D1 | andrographolide results in decreased expression of CCND1 protein |
decreases expression
|
protein |
18619950
|
| C030419 | 1017 |
CDK2
p33(CDK2) |
cyclin-dependent kinase 2 (EC:2.7.11.22) | andrographolide inhibits the reaction [CCNA2 protein binds to CDK2 protein] |
affects binding
/ decreases reaction |
protein |
18619950
|
| C030419 | 1017 |
CDK2
p33(CDK2) |
cyclin-dependent kinase 2 (EC:2.7.11.22) | andrographolide results in decreased expression of CDK2 protein |
decreases expression
|
protein |
18619950
|
| C030419 | 1019 |
CDK4
CMM3 PSK-J3 |
cyclin-dependent kinase 4 (EC:2.7.11.22) | andrographolide inhibits the reaction [CCND1 protein binds to CDK4 protein] |
affects binding
/ decreases reaction |
protein |
18619950
|
| C030419 | 1019 |
CDK4
CMM3 PSK-J3 |
cyclin-dependent kinase 4 (EC:2.7.11.22) | andrographolide results in decreased expression of CDK4 protein |
decreases expression
|
protein |
18619950
|
| C030419 | 1026 |
CDKN1A
CAP20 CDKN1 CIP1 MDA-6 P21 SDI1 WAF1 p21CIP1 |
cyclin-dependent kinase inhibitor 1A (p21, Cip1) | andrographolide results in increased expression of CDKN1A protein |
increases expression
|
protein |
18619950
|
| C030419 | 1544 |
CYP1A2
CP12 P3-450 P450(PA) |
cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) | andrographolide results in decreased expression of CYP1A2 mRNA |
decreases expression
|
mRNA |
19041297
|
| C030419 | 1559 |
CYP2C9
CPC9 CYP2C CYP2C10 CYPIIC9 P450IIC9 |
cytochrome P450, family 2, subfamily C, polypeptide 9 (EC:1.14.13.48 1.14.13.49 1.14.13.80) | andrographolide results in decreased expression of CYP2C9 mRNA |
decreases expression
|
mRNA |
19041297
|
| C030419 | 1576 |
CYP3A4
CP33 CP34 CYP3A CYP3A3 CYPIIIA3 CYPIIIA4 HLP NF-25 P450C3 P450PCN1 |
cytochrome P450, family 3, subfamily A, polypeptide 4 (EC:1.14.13.67 1.14.13.97 1.14.13.32 1.14.13.157) | andrographolide results in decreased expression of CYP3A4 mRNA |
decreases expression
|
mRNA |
19041297
|
| C030419 | 54583 |
EGLN1
C1orf12 ECYT3 HIF-PH2 HIFPH2 HPH-2 HPH2 PHD2 SM20 ZMYND6 |
egl-9 family hypoxia-inducible factor 1 (EC:1.14.11.29) | andrographolide results in increased expression of EGLN1 mRNA |
increases expression
|
mRNA |
21134392
|
| C030419 | 54583 |
EGLN1
C1orf12 ECYT3 HIF-PH2 HIFPH2 HPH-2 HPH2 PHD2 SM20 ZMYND6 |
egl-9 family hypoxia-inducible factor 1 (EC:1.14.11.29) | andrographolide results in increased expression of EGLN1 protein |
increases expression
|
protein |
21134392
|
| C030419 | 54583 |
EGLN1
C1orf12 ECYT3 HIF-PH2 HIFPH2 HPH-2 HPH2 PHD2 SM20 ZMYND6 |
egl-9 family hypoxia-inducible factor 1 (EC:1.14.11.29) | EGLN1 mutant form inhibits the reaction [andrographolide results in decreased expression of HIF1A protein] |
decreases expression
/ decreases reaction |
mutant form |
21134392
|
| C030419 | 54583 |
EGLN1
C1orf12 ECYT3 HIF-PH2 HIFPH2 HPH-2 HPH2 PHD2 SM20 ZMYND6 |
egl-9 family hypoxia-inducible factor 1 (EC:1.14.11.29) | EGLN1 mutant form inhibits the reaction [andrographolide results in decreased expression of VEGFA protein] |
decreases expression
/ decreases reaction |
mutant form |
21134392
|
| C030419 | 54583 |
EGLN1
C1orf12 ECYT3 HIF-PH2 HIFPH2 HPH-2 HPH2 PHD2 SM20 ZMYND6 |
egl-9 family hypoxia-inducible factor 1 (EC:1.14.11.29) | TGFB1 protein inhibits the reaction [andrographolide results in increased expression of EGLN1 mRNA] |
decreases reaction
/ increases expression |
mRNA |
21134392
|
| C030419 | 54583 |
EGLN1
C1orf12 ECYT3 HIF-PH2 HIFPH2 HPH-2 HPH2 PHD2 SM20 ZMYND6 |
egl-9 family hypoxia-inducible factor 1 (EC:1.14.11.29) | TGFB1 protein inhibits the reaction [andrographolide results in increased expression of EGLN1 protein] |
decreases reaction
/ increases expression |
protein |
21134392
|
| C030419 | 2353 |
FOS
AP-1 C-FOS p55 |
FBJ murine osteosarcoma viral oncogene homolog | andrographolide results in decreased localization of and results in decreased activity of FOS protein |
decreases activity
/ decreases localization |
protein |
19426720
|
| C030419 | 3091 |
HIF1A
HIF-1A HIF-1alpha HIF1 HIF1-ALPHA MOP1 PASD8 bHLHe78 |
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | andrographolide inhibits the reaction [HIF1A protein binds to VEGFA promoter] |
affects binding
/ decreases reaction |
protein |
21134392
|
| C030419 | 3091 |
HIF1A
HIF-1A HIF-1alpha HIF1 HIF1-ALPHA MOP1 PASD8 bHLHe78 |
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | andrographolide results in decreased expression of and results in increased degradation of HIF1A protein |
decreases expression
/ increases degradation |
protein |
21134392
|
| C030419 | 3091 |
HIF1A
HIF-1A HIF-1alpha HIF1 HIF1-ALPHA MOP1 PASD8 bHLHe78 |
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | andrographolide results in increased expression of HIF1A protein modified form |
increases expression
|
protein |
21134392
|
| C030419 | 3091 |
HIF1A
HIF-1A HIF-1alpha HIF1 HIF1-ALPHA MOP1 PASD8 bHLHe78 |
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [andrographolide results in increased degradation of HIF1A protein] |
decreases reaction
/ increases degradation |
protein |
21134392
|
| C030419 | 3091 |
HIF1A
HIF-1A HIF-1alpha HIF1 HIF1-ALPHA MOP1 PASD8 bHLHe78 |
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | EGLN1 mutant form inhibits the reaction [andrographolide results in decreased expression of HIF1A protein] |
decreases expression
/ decreases reaction |
protein |
21134392
|
| C030419 | 3725 |
JUN
AP-1 AP1 c-Jun |
jun proto-oncogene | andrographolide results in decreased localization of and results in decreased activity of JUN protein |
decreases activity
/ decreases localization |
protein |
19426720
|
| C030419 | 4316 |
MMP7
MMP-7 MPSL1 PUMP-1 |
matrix metallopeptidase 7 (matrilysin, uterine) (EC:3.4.24.23) | andrographolide results in decreased expression of and results in decreased activity of MMP7 protein |
decreases activity
/ decreases expression |
protein |
19426720
|
| C030419 | 4316 |
MMP7
MMP-7 MPSL1 PUMP-1 |
matrix metallopeptidase 7 (matrilysin, uterine) (EC:3.4.24.23) | andrographolide results in decreased expression of MMP7 mRNA |
decreases expression
|
mRNA |
19426720
|
| C030419 | 5925 |
RB1
OSRC RB p105-Rb pRb pp110 |
retinoblastoma 1 | andrographolide results in decreased phosphorylation of RB1 protein |
decreases phosphorylation
|
protein |
18619950
|
| C030419 | 259296 |
TAS2R50
T2R50 T2R51 TAS2R51 |
taste receptor, type 2, member 50 | andrographolide binds to and results in increased activity of TAS2R50 protein |
affects binding
/ increases activity |
protein |
19817411
|
| C030419 | 7040 |
TGFB1
CED DPD1 LAP TGFB TGFbeta |
transforming growth factor, beta 1 | andrographolide results in decreased expression of TGFB1 protein |
decreases expression
|
protein |
21134392
|
| C030419 | 7040 |
TGFB1
CED DPD1 LAP TGFB TGFbeta |
transforming growth factor, beta 1 | TGFB1 protein inhibits the reaction [andrographolide results in increased expression of EGLN1 mRNA] |
decreases reaction
/ increases expression |
protein |
21134392
|
| C030419 | 7040 |
TGFB1
CED DPD1 LAP TGFB TGFbeta |
transforming growth factor, beta 1 | TGFB1 protein inhibits the reaction [andrographolide results in increased expression of EGLN1 protein] |
decreases reaction
/ increases expression |
protein |
21134392
|
| C030419 | 7157 |
TP53
BCC7 LFS1 P53 TRP53 |
tumor protein p53 | andrographolide results in increased expression of and results in increased phosphorylation of TP53 protein |
increases expression
/ increases phosphorylation |
protein |
18619950
|
| C030419 | 7157 |
TP53
BCC7 LFS1 P53 TRP53 |
tumor protein p53 | andrographolide results in increased expression of TP53 |
increases expression
|
19097688
|
|
| C030419 | 7157 |
TP53
BCC7 LFS1 P53 TRP53 |
tumor protein p53 | Fluorouracil promotes the reaction [andrographolide results in increased expression of TP53] |
increases expression
/ increases reaction |
19097688
|
|
| C030419 | 7422 |
VEGFA
MVCD1 VEGF VPF |
vascular endothelial growth factor A | andrographolide inhibits the reaction [HIF1A protein binds to VEGFA promoter] |
affects binding
/ decreases reaction |
promoter |
21134392
|
| C030419 | 7422 |
VEGFA
MVCD1 VEGF VPF |
vascular endothelial growth factor A | andrographolide results in decreased expression of VEGFA mRNA |
decreases expression
|
mRNA |
21134392
|
| C030419 | 7422 |
VEGFA
MVCD1 VEGF VPF |
vascular endothelial growth factor A | andrographolide results in decreased expression of VEGFA protein |
decreases expression
|
protein |
21134392
|
| C030419 | 7422 |
VEGFA
MVCD1 VEGF VPF |
vascular endothelial growth factor A | EGLN1 mutant form inhibits the reaction [andrographolide results in decreased expression of VEGFA protein] |
decreases expression
/ decreases reaction |
protein |
21134392
|
Related Disease
Diseases related to proteins in ChEMBL interactions
OMIM (28)
| OMIM | preferred title | UniProt |
|---|---|---|
| #202300 | Adrenocortical carcinoma, hereditary; adcc |
P04637
|
| #614740 | Basal cell carcinoma, susceptibility to, 7; bcc7 |
P04637
|
| #114480 | Breast cancer |
P31749
|
| #115200 | Cardiomyopathy, dilated, 1a; cmd1a |
P02545
|
| #212112 | Cardiomyopathy, dilated, with hypergonadotropic hypogonadism |
P02545
|
| #605588 | Charcot-marie-tooth disease, axonal, type 2b1; cmt2b1 |
P02545
|
| #114500 | Colorectal cancer; crc |
P31749
P84022 |
| #615109 | Cowden syndrome 6; cws6 |
P31749
|
| #181350 | Emery-dreifuss muscular dystrophy 2, autosomal dominant; edmd2 |
P02545
|
| #133239 | Esophageal cancer |
P04637
|
| #137800 | Glioma susceptibility 1; glm1 |
O75874
|
| #605130 | Hairy elbows, short stature, facial dysmorphism, and developmental delay |
Q03164
|
| #610140 | Heart-hand syndrome, slovenian type |
P02545
|
| #176670 | Hutchinson-gilford progeria syndrome; hgps |
P02545
|
| #145000 | Hyperparathyroidism 1; hrpt1 |
O00255
|
| #151623 | Li-fraumeni syndrome 1; lfs1 |
P04637
|
| #151660 | Lipodystrophy, familial partial, type 2; fpld2 |
P02545
|
| #613795 | Loeys-dietz syndrome, type 3; lds3 |
P84022
|
| #211980 | Lung cancer |
P04637
|
| #248370 | Mandibuloacral dysplasia with type a lipodystrophy; mada |
P02545
|
| #131100 | Multiple endocrine neoplasia, type i; men1 |
O00255
|
| #613205 | Muscular dystrophy, congenital, lmna-related |
P02545
|
| #159001 | Muscular dystrophy, limb-girdle, type 1b; lgmd1b |
P02545
|
| #260500 | Papilloma of choroid plexus; cpp |
P04637
|
| #176920 | Proteus syndrome |
P31749
|
| #275210 | Restrictive dermopathy, lethal |
P02545
|
| #183090 | Spinocerebellar ataxia 2; sca2 |
Q99700
|
| #275355 | Squamous cell carcinoma, head and neck; hnscc |
P04637
|
KEGG DISEASE (58)
| KEGG | disease name | UniProt |
|---|---|---|
| H00033 | Adrenal carcinoma |
O00255
(related)
P04637 (related) |
| H00034 | Carcinoid |
O00255
(related)
|
| H00045 | Malignant islet cell carcinoma |
O00255
(related)
|
| H00246 | Primary hyperparathyroidism |
O00255
(related)
|
| H01102 | Pituitary adenomas |
O00255
(related)
|
| H00081 | Hashimoto's thyroiditis |
P01215
(marker)
|
| H00082 | Graves' disease |
P01215
(marker)
|
| H00250 | Congenital nongoitrous hypothyroidism (CHNG) |
P01215
(marker)
|
| H00264 | Charcot-Marie-Tooth disease (CMT) |
P02545
(related)
|
| H00294 | Dilated cardiomyopathy (DCM) |
P02545
(related)
|
| H00420 | Familial partial lipodystrophy (FPL) |
P02545
(related)
|
| H00563 | Emery-Dreifuss muscular dystrophy |
P02545
(related)
|
| H00590 | Congenital muscular dystrophies (CMD/MDC) |
P02545
(related)
|
| H00593 | Limb-girdle muscular dystrophy (LGMD) |
P02545
(related)
|
| H00601 | Hutchinson-Gilford progeria syndrome |
P02545
(related)
|
| H00663 | Restrictive dermopathy |
P02545
(related)
|
| H00665 | Mandibuloacral dysplasia |
P02545
(related)
|
| H01216 | Left ventricular noncompaction (LVNC) |
P02545
(related)
|
| H00004 | Chronic myeloid leukemia (CML) |
P04637
(related)
|
| H00005 | Chronic lymphocytic leukemia (CLL) |
P04637
(related)
|
| H00006 | Hairy-cell leukemia |
P04637
(related)
|
| H00008 | Burkitt lymphoma |
P04637
(related)
|
| H00009 | Adult T-cell leukemia |
P04637
(related)
|
| H00010 | Multiple myeloma |
P04637
(related)
|
| H00013 | Small cell lung cancer |
P04637
(related)
|
| H00014 | Non-small cell lung cancer |
P04637
(related)
|
| H00015 | Malignant pleural mesothelioma |
P04637
(related)
|
| H00016 | Oral cancer |
P04637
(related)
P04637 (marker) |
| H00017 | Esophageal cancer |
P04637
(related)
P04637 (marker) |
| H00018 | Gastric cancer |
P04637
(related)
|
| H00019 | Pancreatic cancer |
P04637
(related)
P04637 (marker) |
| H00020 | Colorectal cancer |
P04637
(related)
P04637 (marker) |
| H00022 | Bladder cancer |
P04637
(related)
|
| H00025 | Penile cancer |
P04637
(related)
P04637 (marker) |
| H00026 | Endometrial Cancer |
P04637
(related)
|
| H00027 | Ovarian cancer |
P04637
(related)
|
| H00028 | Choriocarcinoma |
P04637
(related)
|
| H00029 | Vulvar cancer |
P04637
(related)
|
| H00031 | Breast cancer |
P04637
(related)
|
| H00032 | Thyroid cancer |
P04637
(related)
|
| H00036 | Osteosarcoma |
P04637
(related)
P08684 (marker) |
| H00038 | Malignant melanoma |
P04637
(related)
|
| H00039 | Basal cell carcinoma |
P04637
(related)
|
| H00040 | Squamous cell carcinoma |
P04637
(related)
|
| H00041 | Kaposi's sarcoma |
P04637
(related)
|
| H00042 | Glioma |
P04637
(related)
P04637 (marker) |
| H00044 | Cancer of the anal canal |
P04637
(related)
|
| H00046 | Cholangiocarcinoma |
P04637
(related)
|
| H00047 | Gallbladder cancer |
P04637
(related)
|
| H00048 | Hepatocellular carcinoma |
P04637
(related)
|
| H00055 | Laryngeal cancer |
P04637
(related)
P04637 (marker) |
| H00881 | Li-Fraumeni syndrome |
P04637
(related)
|
| H01007 | Choroid plexus papilloma |
P04637
(related)
|
| H00021 | Renal cell carcinoma |
P04637
(marker)
|
| H00539 | PTEN hamartoma tumor syndrome (PHTS) |
P31749
(related)
|
| H00001 | Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia) |
Q03164
(related)
Q03164 (marker) |
| H00002 | Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia) |
Q03164
(related)
|
| H00063 | Spinocerebellar ataxia (SCA) |
Q99700
(related)
|
Diseases related to CTD interactions
5 disease from interactions of metabolites
| MeSH disease | OMIM | compound | disease name | evidence type |
reference
pmid |
|---|---|---|---|---|---|
| D002277 | C030419 | Carcinoma |
therapeutic
|
19426720
|
|
| D015179 | C030419 | Colorectal Neoplasms |
therapeutic
|
19426720
|
|
| C535854 | C030419 | Heavy Metal Toxicity |
therapeutic
|
20946909
|
|
| D008103 | C030419 | Liver Cirrhosis |
therapeutic
|
20946909
|
|
| D008114 | C030419 | Liver Neoplasms, Experimental |
therapeutic
|
19679627
|